2023
18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease
Huang A, Liu S, Barret O, Qiao H, Tamagnan G, Liu X, Fan C, Li Z, Lu J, Chan P, Xu E. 18F-FP-DTBZ PET/CT detectable associations between monoaminergic depletion in the putamen with rigidity and the pallidus with tremor in Parkinson's disease. Parkinsonism & Related Disorders 2023, 120: 105979. PMID: 38241952, DOI: 10.1016/j.parkreldis.2023.105979.Peer-Reviewed Original ResearchPostural instability gait difficultyMotor subtypesParkinson's diseaseStandardized uptake value ratioDifferent motor subtypesStriatal dopaminergic depletionParkinsonian motor symptomsUptake value ratioPET/CTDopaminergic disruptionMonoaminergic depletionMonoaminergic changesDopaminergic depletionMotor symptomsPIGD scoresDorsal putamenPD subtypesVentral putamenPD pathogenesisPrognosis evaluationPatientsDominant subtypeMethods SixtyAccurate diagnosisDifferent subtypesRevisiting Functional Dysconnectivity: a Review of Three Model Frameworks in Schizophrenia
Harikumar A, Solovyeva K, Misiura M, Iraji A, Plis S, Pearlson G, Turner J, Calhoun V. Revisiting Functional Dysconnectivity: a Review of Three Model Frameworks in Schizophrenia. Current Neurology And Neuroscience Reports 2023, 23: 937-946. PMID: 37999830, PMCID: PMC11126894, DOI: 10.1007/s11910-023-01325-8.Peer-Reviewed Original ResearchConceptsNetwork dysconnectivityFunctional dysconnectivityExecutive functioningState fMRI studyAttentional deficitsFMRI studyHypothesized modelSalience networkBrain networksConnectivity findingsBehavioral symptomsNeurodevelopmental modelSymptom severityDysconnectivityHypothesized mechanismsSchizophreniaDeficitsVital modelsSummaryThis paperMotor symptomsFunctioningSymptomsFindingsPurpose of ReviewOverThoughtImpaired pre-synaptic plasticity and visual responses in auxilin-knockout mice
Cheng X, Tang Y, Vidyadhara D, Li B, Zimmerman M, Pak A, Nareddula S, Edens P, Chandra S, Chubykin A. Impaired pre-synaptic plasticity and visual responses in auxilin-knockout mice. IScience 2023, 26: 107842. PMID: 37766983, PMCID: PMC10520332, DOI: 10.1016/j.isci.2023.107842.Peer-Reviewed Original ResearchParkinson's diseasePyramidal cell synapsesVisual cortical functionSilicon probe recordingsPrimary visual cortexShort-term facilitationFamilial Parkinson's diseaseCortical dysfunctionMotor deficitsMotor symptomsCell synapsesCortical functionRepetitive stimulationVisual cortexOptokinetic responseReleasable poolProlonged stimulationLayer 4Visual responsesMiceSynaptic vesiclesEye movementsOrientation selectivityDysfunctionFunction mutations
2021
Reduced cortico-muscular beta coupling in Parkinson’s disease predicts motor impairment
Zokaei N, Quinn A, Hu M, Husain M, van Ede F, Nobre A. Reduced cortico-muscular beta coupling in Parkinson’s disease predicts motor impairment. Brain Communications 2021, 3: fcab179-. PMID: 34514395, PMCID: PMC8421699, DOI: 10.1093/braincomms/fcab179.Peer-Reviewed Original ResearchCortico-muscular coherenceGrip strengthEfficacy of novel treatmentsMotor symptomsParkinson's diseaseMonitoring of disease progressionBeta cortico-muscular coherenceSustained muscle contractionsDisease progressionContralateral forearmHealthy control participantsNovel treatmentDisease groupMuscle contractionDiseaseControl participantsMotor impairmentParkinson's disease groupNeural markersGripParkinson's disease pathologyLong-range communicationMotor cortexSymptomsDisease pathology
2020
Cross-frequency coupling between gamma oscillations and deep brain stimulation frequency in Parkinson’s disease
Muthuraman M, Bange M, Koirala N, Ciolac D, Pintea B, Glaser M, Tinkhauser G, Brown P, Deuschl G, Groppa S. Cross-frequency coupling between gamma oscillations and deep brain stimulation frequency in Parkinson’s disease. Brain 2020, 143: 3393-3407. PMID: 33150359, PMCID: PMC7116448, DOI: 10.1093/brain/awaa297.Peer-Reviewed Original ResearchConceptsDeep brain stimulationBrain stimulationParkinson's diseaseStimulation frequencyCross-frequency couplingMotor symptomsSubthalamic nucleusGamma oscillationsDeep Brain Stimulation FrequencyOscillatory activityPhysiological neural activityMotor function recoveryEffective deep brain stimulationHigh-frequency stimulationPathological oscillatory activityCross-frequency interactionsCortico-subcortical networksDifferent oscillatory activitiesSymptom controlParietal cortex regionsClinical effectsFunction recoverySymptom alleviationMotor impairmentSubcortical regionsImplications of the Gut Microbiome in Parkinson's Disease
Elfil M, Kamel S, Kandil M, Koo BB, Schaefer SM. Implications of the Gut Microbiome in Parkinson's Disease. Movement Disorders 2020, 35: 921-933. PMID: 32092186, DOI: 10.1002/mds.28004.Peer-Reviewed Original ResearchConceptsParkinson's disease patientsDisease patientsParkinson's diseaseMotor symptomsNervous systemEnteric nervous systemGut microbiome dysbiosisGut microbiome changesDifferent body systemsRelease of neurotoxinsCentral nervous systemCommon neurodegenerative disorderNormal gut microbiomeΑ-synuclein aggregatesNonmotor manifestationsAutoimmune responseNeuroprotective factorsAutopsy studyDopaminergic neuronsSubstantia nigraPathophysiologic changesMicrobiome dysbiosisMotor featuresGastrointestinal systemSystemic circulation
2019
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease
Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K, Consortium O. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease. Journal Of Parkinson’s Disease 2019, 9: 553-563. PMID: 31306141, PMCID: PMC6700608, DOI: 10.3233/jpd-191648.Peer-Reviewed Original ResearchConceptsEuropean Medicines AgencyParkinson's diseaseDopamine transporterEnrichment biomarkerClinical trialsPD subjectsParkinson's Progression Markers Initiative (PPMI) studyMotor Parkinson's diseaseParkinson Research ExaminationStriatal DAT bindingUPDRS part IISingle photon emission tomographyAppropriate patient selectionEarly Parkinson's diseaseIdiopathic PD patientsClinical trial populationsFuture clinical trialsClinical trial dataPhoton emission tomographyEarly motor symptomsTest therapeuticsIndependent predictorsTherapeutic trialsDopaminergic deficitMotor symptomsLeigh syndrome caused by mutations in MTFMT is associated with a better prognosis
Hayhurst H, de Coo I, Piekutowska‐Abramczuk D, Alston C, Sharma S, Thompson K, Rius R, He L, Hopton S, Ploski R, Ciara E, Lake N, Compton A, Delatycki M, Verrips A, Bonnen P, Jones S, Morris A, Shakespeare D, Christodoulou J, Wesol‐Kucharska D, Rokicki D, Smeets H, Pronicka E, Thorburn D, Gorman G, McFarland R, Taylor R, Ng Y. Leigh syndrome caused by mutations in MTFMT is associated with a better prognosis. Annals Of Clinical And Translational Neurology 2019, 6: 515-524. PMID: 30911575, PMCID: PMC6414492, DOI: 10.1002/acn3.725.Peer-Reviewed Original ResearchConceptsPathogenic variantsLeigh syndromeSubcortical white matter abnormalitiesNew casesFrequent initial manifestationLast clinical reviewRetrospective cohort studyBasal ganglia changesWhite matter abnormalitiesRespiratory chain deficiencyBi-allelic pathogenic variantsMitochondrial methionyl-tRNA formyltransferaseMolecular genetic findingsMilder clinical phenotypeInitial manifestationBrainstem lesionsCohort studyMedian ageBetter prognosisChain deficiencyMotor symptomsClinical reviewDisease progressionMultiple respiratory chain deficiencyMuscle biopsy
2018
Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
Muthuraman M, Koirala N, Ciolac D, Pintea B, Glaser M, Groppa S, Tamás G, Groppa S. Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease. Frontiers In Neurology 2018, 9: 711. PMID: 30210436, PMCID: PMC6119713, DOI: 10.3389/fneur.2018.00711.Peer-Reviewed Original ResearchDeep brain stimulationL-dopa therapyParkinson's diseaseBrain stimulationEffects of DBSL-DOPAImpact of DBSNon-motor symptomsEffective treatment optionEvidence-based therapiesEffective pharmacological therapyCentral nervous systemBrain networksPerioperative algorithmSpecific brain networksDopaminergic medicationPharmacological therapyClinical effectsMotor symptomsPD patientsPharmacodynamic effectsPharmacological treatmentTherapy optionsTreatment optionsFirst complicationFDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease
Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease. NeuroImage Clinical 2018, 20: 572-579. PMID: 30186761, PMCID: PMC6120603, DOI: 10.1016/j.nicl.2018.08.006.Peer-Reviewed Original ResearchConceptsHealthy controlsDisease-related patternsParkinson's diseaseYahr stagePD patientsClinical trialsParkinson's disease-related patternFluorodeoxyglucose positron emission tomographyGender-matched healthy controlsEarly-stage Parkinson's diseaseMild PD patientsEarly-stage diseaseFDG-PET scansMotor symptom scoresPositron emission tomographyStage diseaseMotor symptomsSymptom scoresFDG-PETDisease stagePD progressionLentiform nucleusParacentral gyrusSymptom evaluationPD subjectsLevodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease
Manza P, Schwartz G, Masson M, Kann S, Volkow ND, Li CR, Leung HC. Levodopa improves response inhibition and enhances striatal activation in early-stage Parkinson's disease. Neurobiology Of Aging 2018, 66: 12-22. PMID: 29501966, PMCID: PMC6436810, DOI: 10.1016/j.neurobiolaging.2018.02.003.Peer-Reviewed Original ResearchConceptsEarly-stage Parkinson's diseaseParkinson's diseaseDopaminergic medicationAdvanced Parkinson's diseaseStriatal activationResponse inhibitionRole of dopaminergicAge-matched controlsFunctional magnetic resonance imagingMagnetic resonance imagingExecutive functionLevodopa monotherapyMultiple medicationsMotor symptomsSignificant group differencesPD groupStop-signal taskAdvanced stageLevodopaResonance imagingMedicationsFunctional connectivityCritical executive functionMotor inhibitionPatients
2017
Cell Replacement Strategies for Parkinson’s Disease
Chatterjee D, Wakeman D, Kordower J. Cell Replacement Strategies for Parkinson’s Disease. Molecular And Translational Medicine 2017, 73-83. DOI: 10.1007/978-3-319-57153-9_4.Peer-Reviewed Original ResearchCell replacement strategiesFetal graftsClinical trialsParkinson's diseaseAnimal modelsDouble-blind clinical assessmentOpen-label clinical trialCareful subject selectionDopamine cell replacementGraft-induced dyskinesiaPotential clinical efficacyProgressive neurodegenerative disorderCell transplantation therapyPrion-like transmissionStem cellsGraft microenvironmentMotor dysfunctionMotor symptomsNigrostriatal pathwayClinical efficacyReplacement therapyDopaminergic neuronsLewy bodiesSpecific therapyCell replacement therapyResponse inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
Manza P, Amandola M, Tatineni V, Li CR, Leung HC. Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects. Npj Parkinson's Disease 2017, 3: 23. PMID: 28702504, PMCID: PMC5501877, DOI: 10.1038/s41531-017-0024-2.Peer-Reviewed Original ResearchDopamine replacement therapyEarly-stage Parkinson's diseaseDisease durationParkinson's diseaseDopaminergic medicationDopaminergic drugsDisease patientsResponse inhibitionCognitive functionDisease duration effectHallmark motor symptomsParkinson's disease durationShorter disease durationAdvanced Parkinson's diseaseParkinson's disease patientsRole of dopamineResponse inhibition deficitsMotor symptomsBasal gangliaHealthy controlsMedication statusMedicationsPatientsCognitive deficitsNeurodegenerative disordersDeep Brain Stimulation Target Selection in an Advanced Parkinson’s Disease Patient with Significant Tremor and Comorbid Depression
Patel AS. Deep Brain Stimulation Target Selection in an Advanced Parkinson’s Disease Patient with Significant Tremor and Comorbid Depression. Tremor And Other Hyperkinetic Movements 2017, 7: 447. PMID: 28428905, PMCID: PMC5395677, DOI: 10.7916/d8kd23nz.Peer-Reviewed Original ResearchGlobus pallidus internaSTN stimulationDisease patientsSubthalamic nucleusParkinson's diseaseAdvanced Parkinson's disease (PD) patientsSignificant short-term improvementsAdvanced Parkinson's diseasePD motor symptomsParkinson's disease patientsShort-term improvementSignificant tremor reductionSTN-DBSMotor symptomsPD patientsRefractory tremorComorbid depressionDBS targetsPD tremorMood disordersBilateral DBSInsufficient evidencePatientsTremor reductionSignificant depressionDeep Brain Stimulation Target Selection in an Advanced Parkinson’s Disease Patient with Significant Tremor and Comorbid Depression
Patel A. Deep Brain Stimulation Target Selection in an Advanced Parkinson’s Disease Patient with Significant Tremor and Comorbid Depression. Tremor And Other Hyperkinetic Movements 2017, 7: 447. DOI: 10.5334/tohm.369.Peer-Reviewed Original ResearchGlobus pallidus internaSTN stimulationDisease patientsSubthalamic nucleusParkinson's diseaseAdvanced Parkinson's disease (PD) patientsSignificant short-term improvementsAdvanced Parkinson's diseasePD motor symptomsParkinson's disease patientsShort-term improvementSignificant tremor reductionSTN-DBSMotor symptomsPD patientsRefractory tremorComorbid depressionDBS targetsPD tremorMood disordersBilateral DBSInsufficient evidencePatientsTremor reductionSignificant depression
2016
Sequence Effect in Parkinson’s Disease Is Related to Motor Energetic Cost
Tinaz S, Pillai AS, Hallett M. Sequence Effect in Parkinson’s Disease Is Related to Motor Energetic Cost. Frontiers In Neurology 2016, 7: 83. PMID: 27252678, PMCID: PMC4877367, DOI: 10.3389/fneur.2016.00083.Peer-Reviewed Original ResearchParkinson's diseaseDopaminergic treatmentIsometric motor tasksVisual feedbackMotor symptomsPD patientsExternal cueingMedication statusPatientsMotor outputRepetitive movementsMajor causeMotor tasksDiseaseHighest motor costMotor plansBradykinesiaMotor controlMotor vigorMotivational cuesRapid decrementTreatmentMorbidityMixed resultsControl
2015
Resting‐state functional connectivity of the striatum in early‐stage Parkinson's disease: Cognitive decline and motor symptomatology
Manza P, Zhang S, Li C, Leung H. Resting‐state functional connectivity of the striatum in early‐stage Parkinson's disease: Cognitive decline and motor symptomatology. Human Brain Mapping 2015, 37: 648-662. PMID: 26566885, PMCID: PMC4843498, DOI: 10.1002/hbm.23056.Peer-Reviewed Original ResearchConceptsParkinson's diseaseFunctional connectivity patternsMotor deficitsFunctional connectivityRostral anterior cingulate cortexState functional connectivity patternsAnterior cingulate cortexConnectivity patternsAnterior putamenMotor symptomsSubstantia nigraDopaminergic functionHealthy controlsMotor functionDorsal caudateStriatal connectivityStriatal subregionsSymptomatic individualsMotor impairmentCingulate cortexCognitive declineNeurodegenerative disordersCognitive functionDiseaseEarly stage individuals
2014
Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys
Barret O, Hannestad J, Alagille D, Vala C, Tavares A, Papin C, Morley T, Fowles K, Lee H, Seibyl J, Tytgat D, Laruelle M, Tamagnan G. Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys. Journal Of Nuclear Medicine 2014, 55: 1712-1718. PMID: 25082853, DOI: 10.2967/jnumed.114.142067.Peer-Reviewed Original ResearchConceptsParkinson's diseaseReceptor occupancyNonhuman primatesPhase 2 clinical trialPET radiotracersRadiation dosimetry estimatesDose-dependent blockingAdult rhesus macaquesAdenosine 2A receptorMotor symptomsSubstantia nigraPlasma levelsClinical trialsHuman pharmacokinetic parametersMotor functionDopamine inputPharmacokinetic parametersReceptor distributionRegional uptakeTozadenantReceptor functionRhesus monkeysWhole-body PET imagesDosimetry estimatesPharmacokinetic modelingCarpal Tunnel Syndrome, Syndrome of Partial Thenar Atrophy, and W. Russell Brain: A Historical Perspective
Boskovski MT, Thomson JG. Carpal Tunnel Syndrome, Syndrome of Partial Thenar Atrophy, and W. Russell Brain: A Historical Perspective. The Journal Of Hand Surgery 2014, 39: 1822-1829.e1. PMID: 25063392, DOI: 10.1016/j.jhsa.2014.05.025.Peer-Reviewed Original ResearchConceptsDistinct clinical entityCarpal tunnel syndromeMedian nerveThenar atrophyIdentifiable causeClinical entityTunnel syndromeCarpal tunnelCarpal ligamentIdiopathic carpal tunnel syndromeAnterior annular ligamentSymptoms of compressionSame clinical pictureTransverse carpal ligamentMotor symptomsThenar branchClinical pictureThenar musclesBrachial plexusSymmetrical atrophyFirst ribThenar eminenceRadial sideNerveAtrophy
2011
Cell Transplantation and Gene Therapy in Parkinson's Disease
Wakeman D, Dodiya H, Kordower J. Cell Transplantation and Gene Therapy in Parkinson's Disease. Annals Of Global Health 2011, 78: 126-158. PMID: 21259269, DOI: 10.1002/msj.20233.Peer-Reviewed Original ResearchConceptsParkinson's diseaseLong-term disease modificationFetal dopamine neuronsGraft-induced dyskinesiaStem cell transplantationCourse of diseaseDirect cell replacementProgressive neurodegenerative disorderWidespread clinical useGene therapyPatient-derived cellsDopamine replacementMotor symptomsDisease modificationDopamine deficiencyViral vector deliveryCell transplantationSymptomatic strategiesDopamine neuronsClinical trialsEfficacy profileDopaminergic circuitryMotor neuronsClinical studiesVentral midbrain
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply